Placenta
Volume 29, Issue 9 , Pages 833-837 , September 2008

Activated Protein C Resistance (APCR) and Placental Fibrin Deposition

  • S. Sedano

      Affiliations

    • National Diagnostics Centre, National University of Ireland, Galway, Ireland
    • Corresponding Author InformationCorresponding author. Tel.: +353 91 492 083/87 773 9718; fax: +353 91 525700.
    • ,
  • G. Gaffney

      Affiliations

    • Department of Obstetrics & Gynaecology, University College Hospital, Galway, Ireland
    • ,
  • G. Mortimer

      Affiliations

    • Department of Pathology, University College Hospital, Galway, Ireland
    • ,
  • M. Lyons

      Affiliations

    • Department of Haematology, University College Hospital, Galway, Ireland
    • ,
  • B. Cleary

      Affiliations

    • Department of Haematology, University College Hospital, Galway, Ireland
    • ,
  • M. Murray

      Affiliations

    • Department of Haematology, University College Hospital, Galway, Ireland
    • ,
  • M. Maher

      Affiliations

    • National Diagnostics Centre, National University of Ireland, Galway, Ireland

,Accepted 25 June 2008.

References 

  1. Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. Faseb J. 1992;6(8):2561–2567
  2. Harris JM, Abramson N. Evaluation of recurrent thrombosis and hypercoagulability. Am Fam Physician. 1997;56(6):1591–15961601-2
  3. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86(1):395–403
  4. Naeye RL. Placental infarction leading to fetal or neonatal death. A prospective study. Obstet Gynecol. 1977;50(5):583–588
  5. Kitzmiller JL, Benirschke K. Immunofluorescent study of placental bed vessels in pre-eclampsia of pregnancy. Am J Obstet Gynecol. 1973;115(2):248–251
  6. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. Bjog. 2001;108(1):56–60
  7. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks’ gestation: associated placental pathologic features. Am J Obstet Gynecol. 1995;173(4):1049–1057
  8. Goddijn-Wessel TAW, Wouters MGAJ, Molen EFVD. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gumecol Reprod Biol. 1996;66:23–29
  9. Gruenwald P. Chronic fetal distress and placental insufficiency. Biol Neonat. 1963;33:215–265
  10. Redline RW, Pappin A. Fetal thrombotic vasculopathy: the clinical significance of extensive avascular villi. Hum Pathol. 1995;26(1):80–85
  11. Sander CM, Gilliland D, Flynn MA, Swart-Hills LA. Risk factors for recurrence of hemorrhagic endovasculitis of the placenta. Obstet Gynecol. 1997;89(4):569–576
  12. Huang ST, Vo KC, Lyell DJ, Faessen GH, Tulac S, Tibshirani R, et al. Developmental response to hypoxia. Faseb J. 2004;18(12):1348–1365
  13. Thaete LG, Dewey ER, Neerhof MG. Endothelin and the regulation of uterine and placental perfusion in hypoxia-induced fetal growth restriction. J Soc Gynecol Investig. 2004;11(1):16–21
  14. Wolf CE, Haubelt H, Pauer HU, Hinney B, Krome-Cesar C, Legler TJ, et al. Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor. Pathophysiol Haemost Thromb. 2003;33(3):134–137
  15. Lunghi B, Castoldi E, Mingozzi F, Bernardi F. A new factor V gene polymorphism (His 1254 Arg) present in subjects of African origin mimics the R2 polymorphism (His 1299 Arg). Blood. 1998;91(1):364–365
  16. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 1998;91(4):1140–1144
  17. Dordevic V, Rakicevic L, Spasic M, Mikovic D, Kovac M, Radojkovic D. [Factor V Leiden, FII G20210A, MTHFR C677T mutations as risk factors for venous thrombosis during pregnancy and puerperium]. Vojnosanit Pregl. 2005;62(3):201–205
  18. Axelsson F, Rosen S. APC resistance. Chromogenix AB. Product Monograph. 1997;1997;Version 2.1
  19. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332(14):912–917
  20. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698–3703
  21. Peng F, Labelle LA, Rainey BJ, Tsongalis GJ. Single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene are common in US Caucasian and Hispanic American populations. Int J Mol Med. 2001;8(5):509–511
  22. Lendrum AC, Fraser DS, Slidders W, Henderson R. Studies on the character and staining of fibrin. J Clin Pathol. 1962;15:401–413
  23. Kraus FT, Redline RW, Gersell DJ, Nelson DM, Dicke JM. Atlas of nontumor pathology 3. American Registry of Pathology; 2004.
  24. Redline RW. Thrombophilla and placental pathology. Clin Obstet Gynecol. 2006;49(4):885–894
  25. Redline R, Boyd T, Campbell V, Hyde S, Kaplan C, Khong T, et al. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Devel Pathol. 2004;7:237–249
  26. Rai RS, Regan L, Chitolie A, Donald JG, Cohen H. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol. 1996;103(8):842–844
  27. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol. 1996;92(2):489–490
  28. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 1997;97(3):551–554
  29. Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod. 1999;14(6):1624–1627
  30. Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114(5–6):409–414
  31. Bane AL, Gillan JE. Massive perivillous fibrinoid causing recurrent placental failure. Br J Obstet Gynaecol. 2003;110:292
  32. Kanfer A, Bruch JF, Nguyen G, He CJ, Delarue F, Flahault A, et al. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest. 1996;74(1):253–258
  33. Livingston JC, Maxwell BD, Sibai BM. Chronic hypertension in pregnancy. Minerva Ginecol. 2003;55(1):1–13
  34. Sheppard BL, Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth retardation. Semin Thromb Hemost. 1999;25(5):443–446
  35. Bremme K, Blomback M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia. Gynecol Obstet Invest. 1996;41(1):20–26
  36. Kupferminc MJ. Thrombophilia and preeclampsia: the evidence so far. Clin Obstet Gynecol. 2005;48(2):406–415
  37. Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol. 2001;98(6):1041–1044
  38. Vern TZ, Alles AJ, Kowal-Vern A, Longtine J, Roberts DJ. Frequency of factor V (Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol. 2000;31(9):1036–1043
  39. Robertson L, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171–196
  40. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel GJ, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol. 2005;106:517–524
  41. Vaughan J, Power C, Nolan C, McCarthy D, Shirley I. The incidence of factor V Leiden in a normal Irish population and its relationship to the laboratory diagnosis of APC resistance. Thromb Haemost 1999; Apr;81(4):661–663.
  42. Livingstone WJ, Keenan C, White B, Mynett-Johnson L, Lawler M, Mayne P, et al. Prevalence of the factor VR506Q mutation in two Irish control populations: use of a novel nested polymerase chain reaction approach. Br J Haematol. 2000;111(2):559–561
  43. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151(9):862–877

PII: S0143-4004(08)00203-8

doi: 10.1016/j.placenta.2008.06.012

Placenta
Volume 29, Issue 9 , Pages 833-837 , September 2008

Article Tools

* Image Usage & Resolution